Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroomi Tada

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Annals of Nuclear Medicine|July 31, 2023
A novel objective method for discriminating pathological and physiological colorectal uptake in the lower abdominal region using whole-body dynamic <sup>18</sup>F-FDG-PETToyohiro Kato, Hajime Ichikawa, Takayuki Shibutani, et al.
The American Journal of Surgical Pathology|January 13, 2005
KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreasRhonda K Yantiss, Bruce A Woda, Gary R Fanger, et al.
Cancer Chemotherapy and Pharmacology|May 3, 2013
Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumorsAntoinette R Tan, Darlene G Gibbon, Mark N Stein, et al.
The Lancet. Oncology|June 24, 2010
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trialRoy S Herbst, Yan Sun, Wilfried E E Eberhardt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2015
HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with CancerChun-Fang Xu, Toby Johnson, Xiaojing Wang, et al.
Cancers|December 23, 2022
Ex Vivo Drug Sensitivity Correlates with Clinical Response and Supports Personalized Therapy in Pediatric AMLDebbie C Strachan, Christine J Gu, Ryosuke Kita, et al.
BMC Medical Ethics|October 23, 2016
Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 studyDavid J Pulford, Philipp Harter, Anne Floquet, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Annals of Nuclear Medicine|July 31, 2023
A novel objective method for discriminating pathological and physiological colorectal uptake in the lower abdominal region using whole-body dynamic <sup>18</sup>F-FDG-PETToyohiro Kato, Hajime Ichikawa, Takayuki Shibutani, et al.
The American Journal of Surgical Pathology|January 13, 2005
KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreasRhonda K Yantiss, Bruce A Woda, Gary R Fanger, et al.
Cancer Chemotherapy and Pharmacology|May 3, 2013
Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumorsAntoinette R Tan, Darlene G Gibbon, Mark N Stein, et al.
The Lancet. Oncology|June 24, 2010
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trialRoy S Herbst, Yan Sun, Wilfried E E Eberhardt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2015
HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with CancerChun-Fang Xu, Toby Johnson, Xiaojing Wang, et al.
Cancers|December 23, 2022
Ex Vivo Drug Sensitivity Correlates with Clinical Response and Supports Personalized Therapy in Pediatric AMLDebbie C Strachan, Christine J Gu, Ryosuke Kita, et al.
BMC Medical Ethics|October 23, 2016
Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 studyDavid J Pulford, Philipp Harter, Anne Floquet, et al.
Pageof 1